spacer
home > epc > summer 2002 > the trials and tribulations of importing clinical trials materials into europe
PUBLICATIONS
European Pharmaceutical Contractor

The Trials and Tribulations of Importing Clinical Trials Materials into Europe

There are a number of key areas that international pharmaceutical companies will need to consider when planning to conduct clinical studies in Europe. Perhaps most importantly, companies need to be aware of several forthcoming regulatory changes, which will be implemented in the next three years as a result of the adoption of the Clinical Trial Directive (2001/20/EC of the European Parliament and of the Council).

Currently, there is no unified regulation governing the import and movement of material around Europe. Local country regulations apply, which in some countries can be as simple as a notification, while in others a formal application is needed. In the UK, for example, all the details of the study materials would be included in the CTX application.

In general terms, the manufacture of clinical materials is not presently required to comply with GMP, but there are some notable exceptions - Germany, for instance, which applies the same GMP to clinical trial materials (CTM) as to a marketed product.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Keren Winmill, Director of Clinical Trial Supplies at Penn Pharmaceutical Services

Keren Winmill is a Pharmacist with 24 years of experience in the pharmaceutical industry. She joined Penn Pharmaceutical Services in 1990 to manage the clinical supplies unit. Keren spent 12 years with Ciba Geigy in Switzerland and in the UK in regulatory affairs, business development and marketing positions.

Keren subsequently joined Quintiles as Director of Business Development, returning to Penn in 1999 as Director of the Clinical Supplies Business Unit. She is responsible for clinical trial packaging and supply management.

spacer
Keren Winmill
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market explored ahead of CPhI MEA

Saudi Arabia’s pharmaceutical market expected to grow at a CAGR of 5.5% until 2023. Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement